Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.

Leukemia & Lymphoma
Gonzalo Bentolila, Astrid Pavlovsky

Abstract

The treatment of classic Hodgkin lymphoma (HL) is a success in onco-hematology. Despite the high cure rate of HL with initial therapy, 5-10% of patients are primary refractory and 10-20% will eventually relapse. The standard treatment for these patients is salvage chemotherapy and autologous stem cell transplantation (ASCT). Only about half of these patients will benefit from this procedure. The prognosis of relapsed refractory (rr) HL has improved with the introduction of effective drugs. With these options available, identification of reliable risk factors is important to guide treatment over the course of disease. Different variables including performance status, anemia, B symptoms, laboratory abnormalities, treatment intensity before ASCT, response to therapy, and duration of remission, have been analyzed to determine risk for progression-free survival (PFS) and overall survival (OS) after ASCT. This review will discuss the publications analyzing these factors, the validated risk scores useful to identify patients at high risk of progression after ASCT, and will describe future perspectives.

References

Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tomás AlvaroMiguel A Piris
Sep 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naoko AsanoShigeo Nakamura
Nov 7, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailLinda J Burns
Nov 9, 2007·The New England Journal of Medicine·Christophe FerméUNKNOWN EORTC-GELA H8 Trial
Oct 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert
May 24, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jacob P SmeltzerTodd A Fehniger
Jun 28, 2011·Leukemia & Lymphoma·Heidi MocikovaTomas Kozak
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
May 28, 2013·Leukemia Research·Carla CasuloCraig H Moskowitz
Mar 23, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P J BröckelmannA Engert
Apr 19, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephanie SasseAndreas Engert
Sep 13, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fong Chun ChanChristian Steidl
Mar 28, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe ArmandStephen M Ansell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Related Papers

Current Hematologic Malignancy Reports
Bastian von Tresckow, Andreas Engert
Blood Reviews
Amanda F Cashen, Nancy L Bartlett
Annals of Oncology : Official Journal of the European Society for Medical Oncology
Carmen MartínezLymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto d
© 2021 Meta ULC. All rights reserved